KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Other Accumulated Expenses: 2018-2025

Historic Other Accumulated Expenses for Twist Bioscience (TWST) over the last 7 years, with Sep 2025 value amounting to $12.1 million.

  • Twist Bioscience's Other Accumulated Expenses rose 108.85% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year increase of 108.85%. This contributed to the annual value of $12.1 million for FY2025, which is 108.85% up from last year.
  • Per Twist Bioscience's latest filing, its Other Accumulated Expenses stood at $12.1 million for Q3 2025, which was up 9.68% from $11.1 million recorded in Q2 2025.
  • Over the past 5 years, Twist Bioscience's Other Accumulated Expenses peaked at $20.1 million during Q2 2022, and registered a low of $4.1 million during Q1 2021.
  • Its 3-year average for Other Accumulated Expenses is $7.9 million, with a median of $7.2 million in 2025.
  • As far as peak fluctuations go, Twist Bioscience's Other Accumulated Expenses spiked by 7,713.46% in 2021, and later crashed by 60.47% in 2023.
  • Over the past 5 years, Twist Bioscience's Other Accumulated Expenses (Quarterly) stood at $13.9 million in 2021, then grew by 14.19% to $15.8 million in 2022, then slumped by 59.44% to $6.4 million in 2023, then declined by 18.32% to $5.2 million in 2024, then surged by 108.85% to $12.1 million in 2025.
  • Its Other Accumulated Expenses was $12.1 million in Q3 2025, compared to $11.1 million in Q2 2025 and $7.2 million in Q1 2025.